Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TKT | P29401 | 3/20 | 0.39 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30492965 | 1.00 | TKT (0.39) | TKTPDCD1LG2CD274KDM4EALDH1A1 | |
| SCHEMBL15951054 | 0.88 | SIRT2 (0.39) | TKTPDCD1LG2CD274SIRT2 | |
| SCHEMBL15951097 | 0.86 | SIRT2 (0.35) | TKTSIRT2 | |
| SCHEMBL844810 | 0.82 | KDM4E (0.40) | TKTKDM4EALDH1A1 | |
| SCHEMBL30968506 | 0.82 | KDM4E (0.40) | TKTKDM4EALDH1A1 | |
| SCHEMBL22982898 | 0.79 | — | — | |
| SCHEMBL29862294 | 0.79 | — | — | |
| SCHEMBL3671495 | 0.79 | TKT (0.43) | TKTPDCD1LG2CD274KDM4EALDH1A1 | |
| SCHEMBL5748559 | 0.78 | ALDH1A1 (0.35) | TKTPDCD1LG2CD274KDM4EALDH1A1 | |
| SCHEMBL846253 | 0.78 | TKT (0.31) | TKT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | RECURSION PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2025061141-A1 | PHARMACEUTICAL COMPOSITION HAVING IMPROVED PHARMACOKINETIC PROPERTIES | 成都思倍博医药科技有限公司 | 2025-03-27 | — | — | WO | disclosed |
| WO-2024222889-A1 | COMPOUND CONTAINING OXO-PYRIDO-ALIPHATIC RING OR ALIPHATIC HETEROCYCLIC STRUCTURE, AND MEDICAL USE THEREOF | 成都思倍博医药科技有限公司 | 2024-10-31 | — | — | WO | disclosed |
| EP-3810275-B1 | 2,3-DIHYDROFURO[2,3-B]PYRIDINE COMPOUNDS | LILLY CO ELI (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3810275-B1 | 2,3-DIHYDROFURO[2,3-B]PYRIDINE COMPOUNDS | LILLY CO ELI (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-112312969-B | 2, 3-dihydrofuro [2,3-b ] pyridine compounds | 伊莱利利公司 | 2023-07-14 | — | — | CN | disclosed |
| US-11214576-B2 | 2,3-dihydrofuro[2,3-b]pyridine compounds | ELI LILLY AND COMPANY (US) | 2022-01-04 | — | — | US | disclosed |
| US-11214576-B2 | 2,3-dihydrofuro[2,3-b]pyridine compounds | ELI LILLY AND COMPANY (US) | 2022-01-04 | — | — | US | disclosed |
| EP-3810275-A1 | 2,3-DIHYDROFURO[2,3-B]PYRIDINE COMPOUNDS | Eli Lilly and Company (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210070766-A1 | 2,3-DIHYDROFURO[2,3-B]PYRIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2021-03-11 | — | — | US | disclosed |
| WO-2010135650-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135650-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | SLC10A1, NR3C2, CYP2C8 | TKT 3717/4885PDCD1LG2 4331/4885CD274 4462/4885 |
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | TKT 4016/4885PDCD1LG2 4619/4885CD274 4184/4885 |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | TKT 1783/4885PDCD1LG2 380/4885CD274 232/4885 |
| US-11214576-B2 | 2,3-dihydrofuro[2,3-b]pyridine compounds | PSEN2, PSEN1, PARK7 | TKT 3659/4885PDCD1LG2 4595/4885CD274 4664/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | TKT 4045/4885PDCD1LG2 4390/4885CD274 4306/4885 |
| US-20210070766-A1 | 2,3-DIHYDROFURO[2,3-B]PYRIDINE COMPOUNDS | PSEN2, PSEN1, PARK7 | TKT 3659/4885PDCD1LG2 4595/4885CD274 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.